This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Big Tech Earnings & Economic Numbers: 3 Ways to Survive the Week Ahead
by Andrew Rocco
Many of the FANG stocks are slated to report earnings this week. Today, we will lay out how investors can best navigate the action packed week ahead.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results likely to reflect rising volumes across all channels.
Zacks Investment Ideas feature highlights: Nvidia, First Solar, Intuitive Surgical, Dexcom and Asure Software
by Zacks Equity Research
Nvidia, First Solar, Intuitive Surgical, Dexcom and Asure Software are part of the Zacks Investment Ideas article.
Riding the Wave: These 3 Industry Groups are Making a Splash with Expected Money Inflows
by Andrew Rocco
Markets have been known to have periods of "nasty" industry group rotation. Get ahead of the curve with these 3 under-the-radar groups.
Are Medical Stocks Lagging DexCom (DXCM) This Year?
by Zacks Equity Research
Here is how DexCom (DXCM) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $116.18, moving +1.56% from the previous trading session.
AngioDynamics (ANGO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -200% and 2.28%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
Dexcom (DXCM) Launches G6 Glucose Monitoring System in Canada
by Zacks Equity Research
Dexcom (DXCM) announces the availability of standard of care in diabetes management - G6 CGM system - for type 1 and 2 patients with basal and bolus insulin or using an insulin pump in Canada.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Should Vanguard Mid-Cap Growth ETF (VOT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VOT
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $118.98, moving +1.51% from the previous trading session.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
DexCom (DXCM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $113.72, moving +0.49% from the previous trading session.
DexCom (DXCM) Stock Moves -0.59%: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $112.08, marking a -0.59% move from the previous day.
5 Stocks That Powered Nasdaq ETF Last Week
by Sweta Killa
The tech-heavy Nasdaq Composite Index outperformed last week, gaining 2.6%, while the S&P 500 and the Dow Jones were up 1.9% and 1.7%, respectively.
DexCom (DXCM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $122.92, moving +1.39% from the previous trading session.
Universal Health (UHS) Q4 Earnings Beat on Solid Segments
by Zacks Equity Research
Universal Health's (UHS) fourth-quarter results indicate growing revenues in its segments resulting from higher patient volumes. Management expects adjusted EPS within $9.50-$10.50 for 2023.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Community Health (CYH) Q4 Earnings Beat on Strong Admissions
by Zacks Equity Research
Community Health's (CYH) fourth-quarter results indicate growing patient volumes. However, management estimates net loss per share to lie between 65 cents and 5 cents in 2023.
DexCom (DXCM) Q4 Earnings Beat Estimates, Volumes Remain Strong
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
DexCom (DXCM) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 30.77% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?